Policy & Regulation
Innovent Biologics doses first diabetic macular oedema patient in phase one IBI324 study
8 August 2022 -

Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company, announced on Sunday that it has dosed its first patient with diabetic macular edema (DME) in the phase one study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

This Phase 1 dose escalations study (CTR20221524) intends to assess the safety and tolerability of intravitreal injection of IBI324 in patients with DME.

IBI324 is a dual-target specific recombinant fully humanised anti-VEGF-A and anti-Ang-2 bispecific antibody developed by the company, which can achieve anti-angiogenesis, vascular stabilisation and inflammation inhibition by blocking both VEGF-A and Ang-2, aiming to provide more potential clinical benefits to DME patients, such as prolonging the dosing interval and improving treatment compliance.